Investigation into the efficacy of Chlorpromazine as a second line therapy for Cannabis Hyperemesis.
Prospective randomised single-blind trial to determine whether standard antiemetic treatment plus chlorpromazine is more effective in reducing episodes of vomiting in patients who present acutely with cannabinoid hyperemesis than standard antiemetic treatment alone.
Charlotte Heldreich
35 participants
Aug 1, 2009
Interventional
Conditions
Summary
This study aims to identify whether the use of chlorpromazine is more effective than standard therapy at treating vomiting associated with Cannabis Hyperemesis Syndrome. The cause of this condition is unknown but similar syndromes of Adult Cylclical vomiting are thought to be related to migraines. Chlorpromazine has been chosen because it is both an antiemetic and anti-migraine therapy.
Eligibility
Inclusion Criteria2
- Intractable vomiting in patients with known cannabis use and no other pathological cause identified.
- Informed consent given.
Exclusion Criteria6
- Declined consent.
- Previous participation
- Grossly abnormal observations or signs of serious pathology.
- Pregnancy
- Allergy to chlorpromazine
- Concurrent use of any drug which is contraindicated with chlorpromazine
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A single dose of metaclopramide 10mg intravenous (iv) and tropisetron 2mg Intravenous (iv) given to all patients in trail. A single dose of Chlorpromazine 25mg in normal saline 1L intravenous (iv) given to treatment group.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000573257